Analysis of first-trimester maternal serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels as a potential non-invasive biomarker for fetal aneuploidy and NTDs
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 2025
DOI: 10.1177/00045632251367280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2025. Verfasst von Karthick E und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Sri Ramachandra Institute of Higher Education and Research, Chennai, India. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Aneuploidy, Pregnancy Trimester, First, Neural Tube Defects. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Sri Ramachandra Institute of Higher Education and Research.
Abstract (Originalsprache)
Objectives
Chromosomal abnormalities and congenital anomalies have huge impact on infant mortality and morbidity. The combined incidence affects approximately 1 per 1000 pregnancies. Current diagnostic modalities include ultrasonography and biomarkers like Beta hCG, PAPP-A and Alpha fetoprotein which have limitations due to their varied sensitivity and specificity in aneuploidy and NTD detection. PCSK9, a proprotein converters appears to have an escalating role in neurogenesis, neuronal differentiation and neurological diseases apart from its role in lipid metabolism. This study estimates serum PCSK9 levels in pregnant women with normal gestation and those with high risk for Aneuploidy and NTDs.
Methods
This prospective case control study included 40 pregnant women with high risk of aneuploidy and NTDs (cases) diagnosed by prenatal screening with ultrasonography findings, Beta HCG, PAPP-A and 40 pregnant women with a healthy singleton pregnancy (controls). Statistical analyses were performed in SPSS software version 16. Fetal and maternal characteristics, serum Beta HCG, PAPP-A, PCSK-9 and aneuploidy risk scores were compared between two groups.
Results
This study observed significant difference in Beta HCG, PAPP-A and PCSK9 levels between the groups ( P < .05). The PCSK9 levels were lower in cases [82.95 (70.41–90.74)] than control group [123.84 (102.515–152.70)]. PCSK9 levels
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
- Clinical Biochemistry and Quality Manager, MGM Healthcare, Chennai, India.
- Department of Laboratory Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
ORCID-Profile: Karthick E, Sathya Selvarajan, Dhivya Senthil Kumar
Förderung
- Sri Ramachandra Institute of Higher Education and Research
Zitieren
APA
E, K., Selvarajan, S., Senthil Kumar, D., K, S., & K S, S. (2025). Analysis of first-trimester maternal serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels as a potential non-invasive biomarker for fetal aneuploidy and NTDs. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. https://doi.org/10.1177/00045632251367280
Vancouver
E K, Selvarajan S, Senthil Kumar D, K S, K S S. Analysis of first-trimester maternal serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels as a potential non-invasive biomarker for fetal aneuploidy and NTDs. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2025. doi:10.1177/00045632251367280
BibTeX
@article{E2025,
author = {E, Karthick and Selvarajan, Sathya and Senthil Kumar, Dhivya and K, Sowmya and K S, Sridharan},
title = {Analysis of first-trimester maternal serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels as a potential non-invasive biomarker for fetal aneuploidy and NTDs},
journal = {Annals of Clinical Biochemistry: International Journal of Laboratory Medicine},
year = {2025},
doi = {10.1177/00045632251367280}
}
EUVIMED